Company News

Clincal Trials and Tribulations Newsletter – May 2022 Edition

Clinical Trials and Tribulations Newsletter - May 2022

Welcome to the May edition of AARDEX Group’s Clinical Trials and Tribulations Newsletter – an aggregated collective of all of the industry’s hottest news and views!  Breaking News New Pivotal Data Demonstrates the Clinical Benefit of Roche’s glofitamab, a Potential First-in-Class Bispecific Antibody for People with Aggressive Lymphoma Roche today announced that new pivotal data…

Read More

In a world of outcome-based pricing, can you afford to neglect patient adherence? 

Poor Patient Adherence

The emergence of outcome-based contracts in clinical research has placed an additional consideration on the already thorny issue of adherence. When drug companies are paid according to the real-world effectiveness of their products, ensuring people take the medications as prescribed is essential to the all-important return on investment (ROI). Modern approaches, such as digital adherence…

Read More

Harnessing Smart Pill Bottles to Improve Patient Adherence in Clinical Research

smart pill bottles

“Nothing stops a drug from working like not taking it, making patient adherence one of the most important factors to consider when designing a clinical trial.”  – Bernard Vrijens, Scientific Lead, AARDEX® Group Poor patient adherence is a problem that has gone “unsolved” for decades. But combining smart pill bottle technology with individualized feedback can drive…

Read More

AARDEX® Group adds etectRx’s Smart Pills to their MEMS® Adherence Hardware ecosystem 

Smart Pills

The partnership sees the integration of AARDEX’s adherence analytics software with etectRx’s ingestible adherence sensor smart pill. Liege, Belgium (APRIL 28, 2022) – Belgium-based AARDEX Group, the leader in measuring and managing medication adherence in clinical trials today announced a strategic partnership with etectRx, Inc. This new collaboration combines etectRx’s smart pill, the ID-Cap™ System, and AARDEX Group’s MEMS Adherence…

Read More

FDA Issues Draft Diversity Guidance to Improve Enrollment of Participants from Underrepresented Patient Populations

FDA Diversity Guidance

Diversity in clinical research is a growing concern for sponsors as many factors can influence how an individual may react to certain drugs: age, biological sex, disabilities, chronic comorbidities, geographical location, gender identity, race, and ethnic background.  Thus, if the investigational product is to be scrutinized for safety and efficacy effectively, a diverse population of…

Read More

Optimizing Study Design to Tackle Protocol Deviations in DCTs

Protocol Deviations in Decentralized Trials

Decentralized Clinical Trials (DCTs) are here to stay, as demonstrated by international regulators’ recent commitments to the model. But while the approach offers a multitude of benefits, from expanding access to increasing cohort diversity, it can also serve to magnify existing protocol deviations such as poor adherence to the dosing regimen. If we are to…

Read More

Harnessing Digital Health Technology to Bolster Study Power

In a world of big tech, data is king. This slogan is far from news for the Biopharmaceutical Industry, but clinical trials are lengthy, complex, and expensive, meaning precious information isn’t always utilized to its maximum potential. In recent years, a slew of Digital Health Technologies (DHTs), designed to collect and share data remotely, have…

Read More